Pain and tingling
neuropathic pain, Pain, cancer, CIPN, pain, Tingling, NRS
DIABETIC PERIPHERAL NEUROPATHY, TINGLING, CANCER
In the present study, NRS score decreased by − 1.5 (27.3%) by week 4 and remained stable at the end of the treatment period (− 1.7, 30.9% reduction at week 12 LOCF). Patients with a baseline NRS of ≥ 6 experienced a − 2.9 reduction (38.7%) in NRS score. Our results are similar to the effects of duloxetine observed in a double-blind placebo-controlled crossover phase 3 study, in which the changes in NRS score were − 1.06 in the duloxetine group and − 0.34 in the placebo group after the initial 5 weeks of treatment [The Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) recommendations state that analgesia can be considered clinical meaningful if it reduces pain severity by ≥ 30% (moderately important improvement) [Tingling is one of the most frequent symptoms in patients with CIPN, but in clinical practice it is often difficult to distinguish between pain and tingling from the patient’s subjective complaints. Previous studies showed that mirogabalin may relieve tingling as well as pain in diabetic peripheral neuropathy [Patients may experience CIPN concurrently with pain related to cancer and/or treatment other than chemotherapy. It is likely difficult for patients to distinguish between CIPN and other causes of pain, and this is a common concern in real-world clinical practice. However, given the pharmacological mechanism of mirogabalin, its analgesic effect in the present study was probably against neuropathic pain. Evidence for this is provided by the consistency between changes in NRS scores for pain (including tingling) and changes in NRS scores for tingling.